Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Accumulated Expenses (2016 - 2025)

Haemonetics (HAE) has 16 years of Accumulated Expenses data on record, last reported at $52.1 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 13.42% year-over-year to $52.1 million; the TTM value through Dec 2025 reached $52.1 million, up 13.42%, while the annual FY2025 figure was $59.4 million, 26.37% down from the prior year.
  • Accumulated Expenses reached $52.1 million in Q4 2025 per HAE's latest filing, up from $48.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $80.7 million in Q1 2024 and bottomed at $30.4 million in Q3 2022.
  • Average Accumulated Expenses over 5 years is $47.6 million, with a median of $46.8 million recorded in 2021.
  • Peak YoY movement for Accumulated Expenses: soared 40.52% in 2021, then fell 26.37% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $41.1 million in 2021, then rose by 27.07% to $52.2 million in 2022, then increased by 12.61% to $58.8 million in 2023, then decreased by 21.83% to $45.9 million in 2024, then rose by 13.42% to $52.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $52.1 million in Q4 2025, $48.3 million in Q3 2025, and $35.8 million in Q2 2025.